State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, China.
Inner Mongolia Key Lab of Molecular Biology, School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, China.
Microbiol Spectr. 2022 Jun 29;10(3):e0221221. doi: 10.1128/spectrum.02212-21. Epub 2022 Apr 6.
Ebola virus, a member of the family, utilizes the attachment factors on host cells to support its entry and cause severe tissue damage. TIM-1 has been identified as a predominant attachment factor via interaction with phosphatidylserine (PS) localized on the viral envelope and glycoprotein (GP). In this study, we give the first demonstration that TIM-1 enhances the cellular entry of three species of Ebola virus, as well as those harboring GP mutations (A82V, T544I, and A82V T544I). Furthermore, two TIM-1 variants (i.e., TIM-1-359aa and TIM-1-364aa) had comparable effects on promoting Zaire Ebola virus (EBOV) attachment, internalization, and infection. Importantly, recombinant TIM-1 ectodomain (ECD) protein could decrease the infectivity of Ebola virus and display synergistic inhibitory effects with ADI-15946, a monoclonal antibody with broad neutralizing activity to Ebola virus. Of note, EBOV strains harboring GP mutations (K510E and D552N), which were refractory to antibody treatment, were still sensitive to TIM-1 protein-mediated impairment of infectivity, indicating that TIM-1 protein may represent an alternative therapeutic regimen when antibody evasion occurs. The viral genome has acquired numerous mutations with the potential to increase transmission during the 2013-to-2016 outbreak of Ebola virus. EBOV strains harboring GP mutations (A82V, T544I, and A82V T544I), which have been identified to increase viral infectivity in humans, have attracted our attention. Herein, we give the first report that polymorphic TIM-1 enhances the infectivity of three species of Ebola virus, as well as those harboring GP mutations (A82V, T544I, and A82V T544I). We show that recombinant TIM-1 ECD protein could decrease the infectivity of Ebola virus with or without a point mutation and displays synergistic inhibitory effects with ADI-15946. Furthermore, TIM-1 protein potently blocked cell entry of antibody-evading Ebola virus species. These findings highlight the role of TIM-1 in Ebola virus infection and indicate that TIM-1 protein represents a potential therapeutic avenue for Ebola virus and its mutated species.
埃博拉病毒属于丝状病毒科,利用宿主细胞上的附着因子来支持其进入并导致严重的组织损伤。TIM-1 已被确定为主要的附着因子,通过与病毒包膜和糖蛋白 (GP) 上定位的磷脂酰丝氨酸 (PS) 相互作用。在这项研究中,我们首次证明 TIM-1 增强了三种埃博拉病毒以及携带 GP 突变 (A82V、T544I 和 A82V T544I) 的病毒的细胞进入。此外,两种 TIM-1 变体(即 TIM-1-359aa 和 TIM-1-364aa)在促进扎伊尔埃博拉病毒 (EBOV) 附着、内化和感染方面具有相当的作用。重要的是,重组 TIM-1 外显子 (ECD) 蛋白可以降低埃博拉病毒的感染力,并与 ADI-15946 显示协同抑制作用,ADI-15946 是一种对埃博拉病毒具有广泛中和活性的单克隆抗体。值得注意的是,携带 GP 突变 (K510E 和 D552N) 的 EBOV 株对抗体治疗有抗性,但仍对 TIM-1 蛋白介导的感染性损害敏感,表明当发生抗体逃逸时,TIM-1 蛋白可能代表一种替代的治疗方案。病毒基因组在 2013 年至 2016 年埃博拉病毒爆发期间获得了许多可能增加传播的突变。携带 GP 突变 (A82V、T544I 和 A82V T544I) 的 EBOV 株已被证明在人类中增加了病毒感染力,引起了我们的注意。在这里,我们首次报告多态性 TIM-1 增强了三种埃博拉病毒以及携带 GP 突变 (A82V、T544I 和 A82V T544I) 的病毒的感染力。我们表明,重组 TIM-1 ECD 蛋白可以降低具有或不具有点突变的埃博拉病毒的感染力,并与 ADI-15946 显示协同抑制作用。此外,TIM-1 蛋白有效地阻止了抗体逃逸的埃博拉病毒种的细胞进入。这些发现强调了 TIM-1 在埃博拉病毒感染中的作用,并表明 TIM-1 蛋白代表了埃博拉病毒及其突变种的一种潜在治疗途径。